Abstract
We investigated whether differences in gut microbiome development could underlie differential susceptibility to gut colonization with extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) over time among children in peri-urban Lima. Weekly stool and daily surveys were collected from 345 children <3 years old during a 2016-19 study of enteric infections. A subset of children (n=12) were rarely gut-colonized with ESBL-E from 1-16 months of age. We performed short-read metagenomic sequencing of stool collected at 3, 6, 7, 9, 12, and 16 months from these children and a random subset of 42 frequently colonized children, and characterized differences in antibiotic use, sociodemographic characteristics, and the gut microbiome over time. No gut microbiome differences were identified, but rarely colonized children were more likely to live in households of lower socioeconomic status and consumed fewer antibiotics. Differences in exposures, rather than gut microbiome development, might underlie patterns of ESBL-E gut colonization among children in peri-urban Lima.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by NIH R01AI108695-01A, NIH award KL2TR002545, and NIH award U19AI110818. MLN was supported by Emory University and the MP3 Initiative. NS was supported by NIH award 5T32ES012870. The content is solely the responsibility of the authors and does not necessarily represent the official views of Emory University or the MP3 Initiative.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The parent cohort study was approved by the Institutional Review Boards of Asociación Benefica PRISMA, Universidad Peruana Cayetano Heredia, and Johns Hopkins University. Written informed consent was obtained from caretakers of the infants for both study participation and the use of collected specimens for subsequent research. The analysis of stool specimens for this substudy was approved by the Institutional Review Boards of Asociación Benefica PRISMA and Universidad Peruana Cayetano Heredia (no. 201592). Metagenomic sequencing of stool specimens was determined to be exempt by the Tufts University Health Sciences IRB (STUDY00001328).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.